Trials / Withdrawn
WithdrawnNCT01162031
Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia
Phase II Study of Bortezomib (VELCADE) for the Treatment of Relapsed or Refractory T-cell Prolymphocytic Leukemia
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
We hope to learn more about the clinical efficacy of bortezomib in T-cell prolymphocytic leukemia. Patients will be selected as a possible participant in this study because they have a bone marrow disorder known as T-cell prolymphocytic leukemia (T-cell PLL) which does not tend to respond well to conventional treatment with chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Velcade | IV |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2010-07-14
- Last updated
- 2018-05-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01162031. Inclusion in this directory is not an endorsement.